Literature DB >> 28759291

Years of life lost due to bronchial asthma in Poland between 1999 and 2013.

Paulina Paciej1, Elżbieta Dziankowska-Zaborszczyk1, Beata Ciabiada1, Marek Bryła2, Irena Maniecka-Bryła1.   

Abstract

OBJECTIVE: The aim of this study was to analyze the years of life lost due to asthma in Poland between 1999 and 2013, with the use of the SEYLL measure (Standard Expected Years of Life Lost).
METHODS: The study was based on a dataset of 5,606,516 records gathered from death certificates of Polish residents from 1999 to 2013. The data on the deaths due to bronchial asthma and status asthmaticus (J45 and J46 according to ICD-10) were used for the analysis. The SEYLL, SEYLLp (SEYLL per person) and SEYLLd (SEYLL per death) were implemented to assess lost life years. The analysis of time trends was performed with the use of the join point model.
RESULTS: In 1999-2013, asthma and status asthmaticus were the cause of 11,380 deaths of Poles (0.20% of all deaths), resulting in 4.23 prematurely lost life years per 10,000 males and 3.22 years per 10,000 females. Over the analyzed years, the value of SEYLL decreased both for men and women. Every man who died due to bronchial asthma in Poland in the studied period, lost on average 19.12 years of life, and every woman 18.20 years.
CONCLUSIONS: The analysis of SEYLL indicated that premature mortality due to asthma is still a meaningful problem in the Polish population and a constant challenge for public health activities.

Entities:  

Keywords:  Bronchial asthma; Poland; SEYLL; diseases of the respiratory system; lost life years premature mortality; potential measures

Mesh:

Year:  2017        PMID: 28759291     DOI: 10.1080/02770903.2017.1355382

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  1 in total

1.  Standard expected years of life lost (SEYLL) due to chronic obstructive pulmonary disease (COPD) in Poland from 1999 to 2014.

Authors:  Elzbieta Dziankowska-Zaborszczyk; Marek Bryla; Beata Ciabiada-Bryla; Irena Maniecka-Bryla
Journal:  PLoS One       Date:  2019-03-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.